Salcit Technologies

Point of care, AI-enabled respiratory diagnostic platform


As on August 2023


Swaasa AI deployed in health facilities


People screened

Geographical Focus
  • PAN India
Potential Impact
  • Reach

    168000 Million

    lives across 24 health centres

Samridh support

SAMRIDH’s financial support is enabling Salcit to establish the use case and price point for “Swaasa AI” platform through its deployment in 24 rural and remote health centres. Furthermore, SAMRIDH will also support Salcit to integrate Swaasa with National TB Elimination Program (NTEP), COVID-19 programs and other health schemes. Through this financial assistance, Salcit aims to scale up their diagnostics across 24 healthcare centres.



India bears global burden of respiratory diseases



Every third respiratory disease patient who dies or contributes to DALYs is from India 1



Every sixth person with respiratory disease lives in India. 2

At 32%, India bears a disproportionately high burden of global DALYs from chronic respiratory diseases. COVID-19, together with “long COVID” (prolonged respiratory discomfort), and Tuberculosis (TB) have further contributed to the country’s respiratory burden, with limited healthcare resources for the increased number of patients. While timely diagnosis and treatment of respiratory diseases can save lives, screening and diagnostic services remain inaccessible and unaffordable for underserved areas and communities. Currently, most diagnostic services require specialist skills and fully functional laboratory facilities which makes them costly. In this scenario, it is essential to strengthen affordable mass-scale screening and diagnosis of respiratory diseases and initiate timely treatments.

Swaasa AI

Salcit has developed the “Swaasa AI”, a proprietary platform that can screen people for lung conditions by analysing the recording of a 10-second audio clip of solicited cough. Using artificial intelligence algorithms and machine learning, this one-of-a-kind platform provides an instant evaluation of respiratory health. The audio can either be recorded using the Swaasa AI mobile application, or it can later be relayed into the Swaasa AI system. The audio can be analysed remotely and does not require specialists to be present on-site, thereby eliminating deployment costs. The solution is easy to use, cost-effective and makes respiratory diagnoses accessible and affordable for hard-to-reach areas and underserved communities.